Clinical Trial Update: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and tolerability of immunotherapy combinations in triple-negative breast cancer and ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Arcus Biosciences, Inc. | Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED